Sugi Predict

Sugi Predict / Compounds / SCHEMBL899349

SCHEMBL899349

SCHEMBL899349

CC1(C)OCC(CC=O)O1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ TMEM97 Q5BJF2 2/20 0.35
▸ SIGMAR1 Q99720 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18767034 1.00 CA2 (0.47) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL3054401 1.00 CA2 (0.47) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL27613931 0.81 CA2 (0.44) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL7152435 0.80 CA2 (0.45) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL7156770 0.80 CA2 (0.45) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL10027876 0.79 CA2 (0.43) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL12400279 0.79 CA2 (0.43) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL12399571 0.79 CA2 (0.43) CA2ALDH1A1NPSR1TMEM97SIGMAR1
SCHEMBL12976171 0.76 — —
SCHEMBL13305488 0.76 CA2 (0.41) CA2ALDH1A1NPSR1TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717316-A2 ANTI-EGFR ANTIBODY-DRUG CONJUGATES AbbVie Inc. (US) 2026-04-01 — — EP disclosed
US-20250213685-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2025-07-03 — — US disclosed
US-20250177374-A1 BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same ABBVIE INC (US) 2025-06-05 — — US disclosed
US-20250171435-A1 Carbon Linked BCL Inhibitors and Senolytic Compounds and Uses Thereof Rubedo Life Sciences, Inc. 2025-05-29 — — US disclosed
US-20250170263-A1 ANTI-EGFR ANTIBODY-DRUG CONJUGATES ABBVIE INC (US) 2025-05-29 — — US disclosed
EP-4364754-A2 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2024-05-08 — — EP disclosed
US-20240115725-A1 Anti-EGFR Antibody-Drug Conjugates ABBVIE INC (US) 2024-04-11 — — US disclosed
US-20240058450-A1 BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same ABBVIE INC (US) 2024-02-22 — — US disclosed
EP-4281117-A1 ANTI-EGFR ANTIBODY-DRUG CONJUGATES AbbVie Inc. (US) 2023-11-29 — — EP disclosed
CN-117015404-A Anti-EGFR antibody drug conjugates 艾伯维公司 2023-11-07 — — CN disclosed
US-20070060590-A1 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2007-03-15 — — US disclosed
US-20070060590-A1 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2007-03-15 — — US disclosed
EP-1234885-A1 A process for the preparation of beta-hydroxy-delta-lactone using novel intermediates Council of Scientific & Industrial Research (IN) 2002-08-28 — — EP disclosed
US-6417374-B1 Process for the preparation of beta hydroxy-delta lactone using novel intermediates COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2002-07-09 — — US disclosed
US-4945105-A ANTHEMINTICS, MITICIDES, INSECTICIDES SANKYO COMPANY LIMITED (JP) 1990-07-31 — — US disclosed
US-4820758-A Novel [5.5]-spiroketals THE UPJOHN COMPANY (US) 1989-04-11 — — US disclosed
US-4814347-A ANTIBIOTIC INTERMEDIATE THE UPJOHN COMPANY (US) 1989-03-21 — — US disclosed
US-4812582-A ANTHEMINTIC INTERMEDIATES THE UPJOHN COMPANY (US) 1989-03-14 — — US disclosed
US-4686297-A Anthelmintic spiroketals useful for killing parasitic worms THE UPJOHN COMPANY (US) 1987-08-11 — — US disclosed
US-4680419-A ANTHELMINTICS THE UPJOHN COMPANY (US) 1987-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170263-A1 ANTI-EGFR ANTIBODY-DRUG CONJUGATES EGFR, ERBB3, ERBB2 CA2 2796/4885ALDH1A1 3490/4885NPSR1 2260/4885
US-20250213685-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 CA2 2461/4885ALDH1A1 1891/4885NPSR1 2055/4885
US-20070060590-A1 6-Membered heterocyclic compound and use thereof WNT1, CYP11B2, CYP11B1 CA2 775/4885ALDH1A1 1638/4885NPSR1 4731/4885
US-20250171435-A1 Carbon Linked BCL Inhibitors and Senolytic Compounds and Uses Thereof BCL2, BCL2A1, BCL2L1 CA2 2083/4885ALDH1A1 1453/4885NPSR1 4673/4885
US-20240115725-A1 Anti-EGFR Antibody-Drug Conjugates EGFR, ERBB2, ERBB3 CA2 2743/4885ALDH1A1 1828/4885NPSR1 3020/4885
US-20250177374-A1 BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same BCL2, BAX, BCL9 CA2 2615/4885ALDH1A1 2826/4885NPSR1 4409/4885
US-20240058450-A1 BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same BCL2, BAX, BCL9 CA2 2615/4885ALDH1A1 2826/4885NPSR1 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.